Scholars Central

Conference abstractPublished 21 Nov 2016

Prolactin pro-differentiation pathway in triple negative breast cancer: Impact on prognosis and potential therapy

Authors: Vanessa M Lopez Ozuna, Ibrahim Hachim, Mahmood Hachim, Suhad Ali

McGill University, Canada

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Triple negative breast cancer (TNBC) is a heterogeneous disease associated with poor clinical outcome and lack of targeted therapy. TNBC tumor cells are characterized by the loss of epithelial differentiation phenotype and the acquisition of stem celllike mesenchymal features with high tumor-initiating capacity. The hormone prolactin (PRL) is a well-established differentiation factor for mammary epithelial cells. Here we examined the role of prolactin-mediated differentiation pathway in prognosis, subclassification and potential therapeutic option in TNBC. Our findings showed that PRL and its signaling pathway serve as a subclassifier and predictor of pro-differentiation therapy in TNBC. Using immunohistochemistry and various gene expressions in silica analyses, we observed that prolactin receptor (PRLR) protein and mRNA levels are down regulated in TNBC cases. In addition, examining correlation of PRLR gene expression with metagenes of TNBC subtypes (580 cases), we found that PRLR gene expression sub-classifies TNBC patients into a new subgroup (TNBC-PRLR) characterized by epithelial-luminal differentiation. Importantly, gene expression of PRL signaling pathway components individually (PRL, PRLR, Jak2 and Stat5a), or as a gene signature, is able to predict TNBC patients with significantly better survival outcomes. As PRL hormone is a druggable target, we determined the biological role of PRL in TNBC biology. Significantly, restoration/activation of PRL pathway in TNBC cells representative of mesenchymal or TNBC-PRLR subgroups led to induction of epithelial phenotype and suppression of tumorigenesis. Altogether, these results offer potential new modalities for TNBC stratification and development of personalized therapy based on PRL pathway activation.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Vanessa M Lopez Ozuna”
  • BylineArticles whose byline prints “Ibrahim Hachim”
  • BylineArticles whose byline prints “Mahmood Hachim”
  • BylineArticles whose byline prints “Suhad Ali”